An observational study in Breast Cancer, sponsored by Assiut University. Not yet recruiting. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-01.
Sponsored by Assiut University · Observational
This study examines certain molecular markers in breast cancer using blood and tissue samples from routine diagnostic biopsies. No extra procedures will be performed on patients. The goal is to improve understanding of disease mechanisms and identify potential targets for treatment
This is an observational, case-control study designed to evaluate the expression of lncRNA PCGEM1 and its association with related molecular pathways, including RhoA, TRIAP1, and ferroptosis, in breast cancer patients. The study will include patients diagnosed with breast cancer and a matched control group.
No intervention will be performed as part of this study. Tissue samples will be obtained from routine diagnostic biopsies that are already indicated as part of standard clinical care, with no additional procedures carried out for research purposes.
Collected tissue samples will be processed for RNA extraction and subsequent molecular analysis to assess gene expression levels. The results will be analyzed to explore the potential role of PCGEM1 in tumor progression and its correlation with selected molecular pathways.
The findings of this study may contribute to a better understanding of breast cancer biology and help identify potential biomarkers or therapeutic targets.
12,544 studies on the registry are indexed under Breast Neoplasms; 2,892 are open to participants now.
This study's planned enrollment of 90 is below the median of 184 across 2,642 observational studies indexed under Breast Neoplasms.
Browse Breast Neoplasms studies →Assiut University is the lead sponsor of 4,901 studies on the registry; 2,098 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
18 years and older newly diagnosed female patients with histopathological confirmation of the diagnosis of breast cancer at any stage and matched control
Exclusion Criteria:
Device: No Biologics
No intervention will be performed in this study. Tissue samples will be obtained from routine diagnostic biopsies that are already indicated as part of standard clinical care
Relative expression level of PCGEM1 marker in breast cancer tissue and blood sample
This outcome measures the relative expression level of PCGEM1 in breast cancer tissue and blood samples compared to control using quantitative real-time PCR (qRT-PCR). The results will be correlated with clinicopathological parameters.
Time frame: at base line
No study locations are listed for this record.
This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assiut University